Gabapentin Capsule
Product Images NDC 0904-7613

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 0904-7613). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100 mg100 Unit-dose Label (Gabapentin Cap 100 100c)

Box packaging label for Gabapentin Capsules USP 100 mg by Major Pharmaceuticals. The label states a quantity of 100 capsules (10x10) in unit dose packaging. It includes storage instructions, manufacturer information (Alkem Laboratories Ltd., Mumbai, India), and distributor details for Major Pharmaceuticals in Indianapolis, IN. The label features the NDC 0904-7613-61 and a barcode.*

FDA Label Image

300 mg100 Unit-dose Label (Gabapentin Cap 300 100c)

Major Pharmaceuticals Gabapentin 300 mg capsules unit dose packaging label. The label indicates 100 capsules (10x10) with instructions for pharmacists to dispense the enclosed Medication Guide to patients. It includes storage instructions of 20 to 25°C, manufacturing by Alkem Laboratories Ltd. India, and distribution by Major Pharmaceuticals, Indianapolis, IN, USA. The label features barcodes and a revision date of 09/25.*

FDA Label Image

400 mg100 Unit-dose Label (Gabapentin Cap 400 100c)

Gabapentin Capsules USP 400 mg unit dose packaging label by Major Pharmaceuticals. Contains 100 capsules (10x10). The label includes storage instructions to keep between 20° to 25°C and directs pharmacists to dispense the enclosed Medication Guide. Manufactured by Alkem Laboratories Ltd., India, and distributed by Major Pharmaceuticals, Indianapolis, IN.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

An equation illustrating the calculation of creatinine clearance (CLCr), which includes variables for age in years, weight in kilograms, serum creatinine in mg/dL, and an adjustment factor of 0.85 for female patients.*

FDA Label Image

Structure (Gabapentin Fig 5)

Chemical structure of gabapentin, showing the cyclohexane ring bonded to a carbon with amino (CH2NH2) and carboxyl (CH2CO2H) functional groups.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph depicting mean pain scores over 8 weeks comparing placebo and gabapentin 3600 mg/day. The x-axis represents weeks including a 4-week dose titration period and a 4-week fixed dose period. The y-axis shows mean pain scores from 0 to 10. Gabapentin group shows a decrease in pain scores over time, while placebo remains relatively stable.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph plotting mean pain scores over seven weeks, comparing placebo and two dosages of gabapentin (1800 mg/day and 2400 mg/day). The x-axis represents weeks including baseline, while the y-axis shows pain scores from 0 to 10. The graph highlights a 3-week dose titration period followed by a 4-week fixed dose period.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar graph showing the proportion of responders with at least 50% reduction in pain score at endpoint from controlled PHN studies. It compares placebo (PBO) with Gabapentin (GBP) at doses 3600 mg in Study 1, and 1800 mg and 2400 mg in Study 2, with response percentages ranging from 12% to 34%, highlighting statistical significance levels (p < 0.01 and p < 0.001).*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A scatter plot chart depicting the difference percentage on the y-axis versus daily dose in mg on the x-axis for Gabapentin. The chart compares three studies (STUDY a, STUDY b, STUDY c) with distinct markers and shows data points at daily doses approximately 600 mg, 900 mg, 1200 mg, and 1800 mg.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.